ATHE

Alterity Therapeutics Limited

Investor Moves

NameValueActionChangePriceCurrent Price
Ken GriffinCitadel Advisors
$71k20.1k shares
AddQ1 2026
$20k
$3.56
$4.08
Steven CohenPoint72
$-537.3K
ExitQ3 2025
$537k
--
$4.08
Steven CohenPoint72
$83.9K
AddQ2 2025
$84k
--
$4.08
Steven CohenPoint72
$345.4K
AddQ1 2025
$345k
--
$4.08

News

benzinga.comAlterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorderbenzinga.comJun 9globenewswire.comAlterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophyglobenewswire.comJun 9globenewswire.comAlterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophyglobenewswire.comMay 19globenewswire.comAlterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophyglobenewswire.comMay 11globenewswire.comAlterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026globenewswire.comMay 7